Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
MPI unblinds prospective study of LungChip prognosticator in early lung cancer | ||
By: Nasdaq / GlobeNewswire - 27 Nov 2015 | Back to overview list |
|
Hoersholm; November 27, 2015 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that the prospective LungChip study has been unblinded. LungChip is a prognostic tool for predicting which patients have a good or a bad prognosis of their lung cancer, which can have impact on treatment. The study has been performed at oncology departments in USA and Denmark and data from 135 patients diagnosed with early stage 1A Non Small Cell Lung Cancer have been analyzed during the study which has been ongoing for more than five years.
Patients from this study were diagnosed with stage 1A, Non Small Cell Lung Cancer where the tumor was smaller than 3 cm with no spreading of the disease for instance to lymph nodes so the cancer could be removed completely by surgery. In this group of patients there is a smaller fraction with a more aggressive type of cancer where adjuvant chemotherapy administered right after surgery could be considered. It is specifically these patients MPI's LungChip prognosticator can identify. MPI will now discuss a plan for commercialization of the new test with potential partners. " We look forward to when MPI's LungChip prognostic test can be offered to those identified with the most aggressive form of lung cancer enabling earlier treatment than what is available today," says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO in MPI . As we in addition can use MPI's Drug Response Prediction technology - DRP(TM) to predict who will respond positively to chemotherapy, this is a unique research tool to for the treatment of lung cancer in all stages", Peter Buhl Jensen continues .
About MPI
About MPI's LungChip
About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
For further information, please contact
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medical Prognosis Institute via GlobeNewswire
HUG#1969857
|
||
|
||
Copyright 2015 Nasdaq / GlobeNewswire | Back to overview list |